Verition Fund Management
ALGS icon

Verition Fund Management’s Aligos Therapeutics ALGS Stock Holding History

Verition Fund Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$140K Sell
18,887
-52,367
-73% -$397K ﹤0.01% 2001
2025
Q4 		$664K Buy
+71,254
New +$672K ﹤0.01% 2456

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Verition Fund Management's ALGS Position: Q1 2026 in Review

Verition Fund Management reduced its Aligos Therapeutics (ALGS) stake by 73% in Q1 2026, selling an estimated $397K and leaving 18,887 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #2001.

Verition Fund Management first reported a position in ALGS in Q4 2025 and has held it in 2 quarters since. The position peaked at $664K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Verition Fund Management held 18,887 shares of Aligos Therapeutics worth $140K as of Q1 2026.
  • Verition Fund Management sold 52,367 Aligos Therapeutics shares in Q1 2026, an estimated $397K.
  • Aligos Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #2001 holding.
  • Verition Fund Management first reported a position in Aligos Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Verition Fund Management's Aligos Therapeutics position peaked at $664K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.